Table of Content 1. Chronic Myeloproliferative Diseases (MPD) 2. Myelodysplastic Syndromes (MDS) Classification of myelodysplasic syndromes 2015 3. Treatment Related Leukaemias (t-AML) 4. Acute Myeloid Leukaemias (AML) Classification of acute myeloid leukemias 5. B-Cell Acute Lymphocytic Leukaemias (B-ALL) 6. T-Cell Acute Lymphocytic Leukaemias (T-ALL) 7. Non Hodgkin Lymphomas and Chronic Lymphoproliferative Diseases (NHL and CLD) 8. Not Classified 1. Chronic Myeloproliferative Diseases (MPD) Unbalanced whole-arm translocation der(1;10)(q10-q11;p10-p12) der(11)t(1;11)(q11-23;q14-25) t(1;11)(q24;p15) NUP98::PRRX1 t(11;22)(q13;q13) HRASLS5::PHF21B t(1;12)(p36;p13) ETV6::MDS2 t(1;12)(q21;p13) ETV6::ARNT Unbalanced whole-arm translocation der(1;13) in hematologic malignancies der(1;14)(p10 or q10;p10 or q10) der(15)t(1;15)(q11-12;p11-13) and der(15)t(1;15)(q21-25;p10-13) dic(1;15)(p11;p11) t(1;18)(q10;q10) t(1;19)(p13;p13.1) dup (11q) in myeloid malignancies der(20)t(1;20)(q10-21;q11-13) der(20)t(1;20)(q12-21;p13) in hematological malignances t(12;13)(p12;q12-14) ETV6::CDX2 t(12;13)(p13;q12) ETV6::FLT3 t(12;13)(p13;q14) LIN00598::ETV6 t(12;22)(p13;q12) MN1::ETV6 del(12)(q24q24) SETD1B::GTF2H3 t(1;2)(p36;p21) THADA::PRDM16 del(13q) in myeloid malignancies del (13q) t(1;3)(p36;q21) PSMD2::PRDM16 ??? t(1;3)(p36;p21) +14 or trisomy 14 (solely) der(5)t(1;5)(q12-q25;q13-q35) t(1;5)(q21;q33) (MPD; TPM3::PDGFRB; rare) t(1;5)(q21-23;q31-33) t(1;5)(q21-23;q32) TPM3::PDGFRB t(1;5)(q21;q32) PDE4DIP::PDGFRB der(6)t(1;6)(q21-23;p21) del(16)(q22) CBFB::MYH11 inv(16)(p13q22) CBFB::MYH11 t(16;16)(p13;q22) CBFB::MYH11 +16 or trisomy 16 (solely) i(17q) solely in myeloid malignancies der(1;7)(q10;p10) der(17)t(17;17)(p13;q12-21) del(18)(p11) i(18)(q10) der(1;9)(q10;p10) der(9)t(1;9)(q11-12;q34) der(9)t(1;9)(q12;q12) dup(1)(q11-q44) in myeloid malignancies der(1)t(1;1)(p36;q11-q32) in hematopoietic malignancies 1q triplication in hematologic malignancies 1q translocations (unbalanced) in myeloid malignancies del(20q) in myeloid malignancies -20 or monosomy 20 +20 or trisomy 20 (solely) t(2;11)(p21;q23) without KMT2A (MLL) rearrangement t(2;11)(p21;q24) MIR125B1::? t(2;13)(p16;q12) SPTBN1::FLT3 -21 or monosomy 21 (solely) i(22)(q10) in myeloid malignancies t(2;3)(p15-23;q26-27) ?::MECOM t(2;4)(p22;q12) STRN::PDGFRA t(2;4)(p23;q25-q35) t(2;5)(p21;q33) SPTBN1::PDGFRB t(3;11)(q26;p15) ?::MECOM t(3;12)(q26;p13) ETV6::EVI1 t(3;12)(q26;p13) ETV6::MECOM t(3;17)(q26;q22) ?::MECOM t(3;21)(q26;q22) RUNX1::MECOM 3q26 rearrangements (MECOM) in myeloid malignancies t(3;5)(q25;q34) NPM1::MLF1 t(3;7)(q26;q21) CDK6::MECOM inv(3)(p12q26) ?::MECOM inv(3)(q23q26) ?::MECOM der(3)t(3;3)(p25-26;q12-21) t(4;10)(q12;p11) KIF5B::PDGFRA t(4;10)(q12;q23) PDGFRA::TNKS2 t(4;12)(q12;p13) PDGFRA::ETV6 t(4;17)(q12;q21) FIP1L1::RARA t(4;21)(q35;q22) RUNX1::? t(4;22)(q12;q11) BCR::PDGFRA t(4;5)(q21;q33) PRKG2::PDGFRB ins(9;4)(q33;q12q25) CDK5RAP2::PDGFRA t(5;10)(q33;q21) CCDC6::PDGFRB t(5;11)(q31;q23) KMT2A::ARHGAP26 t(5;11)(q33;p13) CAPRIN1::PDGFRB t(5;12)(q33;p13) ETV6::PDGFRB t(5;12)(q31;p13) ETV6::ACSL6 in MDS,AML and AEL t(5;12)(q33;q24) GIT2::PDGFRB t(5;14)(q33;q24) NIN::PDGFRB t(5;14)(q33;q32) PDGFRB::CCDC88C t(5;15)(q33;q22) TP53BP1::PDGFRB dic(5;17)(q11-14;p11-13) t(5;9)(q32;p24) KANK1::PDGFRB i(5)(p10) in hematological malignancies del(6p) (loss of JARID2 and DTNBP1) in myeloid malignances +6 or trisomy 6 t(7;11)(p15;p15) NUP98::HOXA9 t(7;11)(p15;p15) NUP98::HOXA13 dic(7;12)(p10-p12;p11-p13) t(7;14)(p13;q11) t(7;14)(q21;q13) t(7;17)(p15;q23) MSI2::HOXA9 t(7;17)(q32-34;q23) MSI2::? del(7)(p11-15) solely i(7)(q10) in myeloid malignancies ins(12;8)(p13;q11q21) ETV6::LYN ins(12;8)(p11;p12p22) FGFR1OP2::FGFR1 t(8;12)(p12;p11) FGFR1OP2::FGFR1 t(8;12)(p12;q15) CPSF6::FGFR1 t(8;12)(q22;q13) HMGA2::? t(8;14)(q11;q32) IGH::CEBPD t(8;17)(p11;q23) MYO18A::FGFR1 t(8;17)(p11;q25) ?::FGFR1 t(8;17)(q13;q23) t(8;22)(p11;q11) BCR::FGFR1 8p11 myeloproliferative syndrome (FGFR1) t(8;9)(p12;q33) CNTRL::FGFR1 +8 or trisomy 8 t(9;12)(p24;p13) ETV6::JAK2 t(9;14)(q33;q32) IGH::LHX2 der(9;18)(p10;q10) t(9;22)(q34;q11) BCR::ABL1 in CML t(9;22)(p24;q11.2) BCR::JAK2 Atypical Chronic Myeloid Leukemia (aCML) Chronic Eosinophilic Leukemia-Not Otherwise Specified (CEL-NOS) Idiopathic Hypereosinophilic Syndrome (IHES) Chronic myelogenous leukaemia (CML) Cutaneous mastocytosis Essential Thrombocythemia (ET) Juvenile myelomonocytic leukemia (JMML) Myelodysplastic::myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) Myelodysplastic::myeloproliferative neoplasms Agnogenic myeloid metaplasia Idiopathic myelofibrosis Myelofibrosis with Myeloid Metaplasia (MMM) Myeloid::Lymphoid neoplasms with abnormalities of PDGFRA Myeloid::Lymphoid neoplasms with abnormalities of PDGFRB Myeloid::lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2: Overview 2019 Polycythemia Vera (PV) del(9q) solely i(9)(p10) +9 or trisomy 9 t(X;20)(q13;q13.3) t(X;21)(p11;q22) RUNX1::? i(X)(p10) in female patients i(Xq10) in female patients +X solely in myeloid malignancies der(Y)t(Y;1)(q11-12;q12-21) t(Y;1)(q12;q12) Y loss in leukemia 2. Myelodysplastic Syndromes (MDS) t(10;12)(q24;p13) ETV6::GOT1 11q23 rearrangements (KMT2A) in leukaemia t(11;14)(p15;q22) AP2A2::NID2 t(11;16)(q23;p13.3) KMT2A::CREBBP t(11;17)(q23;q25) KMT2A::SEPT9 t(11;17)(p15;q21) NUP98::? t(11;20)(p15;q11) NUP98::TOP1 t(11;21)(q13;q22) RUNX1::MACROD1 der(12)t(1;12)(q11-21;p11-13) t(1;16)(q11;q11) der(18)t(1;18)(q10-25;q11-23) inv(11)(p15q23) NUP98::KMT2A inv(11)(q21q23) KMT2A::MAML2 in therapy related leukemias MLL amplification in leukemia +11 or trisomy 11 (solely) KMT2A 12p abnormalities in myeloid malignancies t(12;14)(q13;q31) HMGA2::? t(12;15)(p13;q25) ETV6::NTRK3 in Hematological malignancies t(12;17)(p13;p13) ETV6::PER1 t(12;18)(p13;q12) ETV6::SETBP1 t(1;21)(p36;q22) RUNX1::PRDM16 der(21)t(1;21)(q11-12;p11-13) and der(21)t(1;21)(q21-32;p11-13) t(12;20)(q15;q11.2) HMGA2 truncated inv(12)(p13q15) ETV6::PTPRR der(2)t(1;2)(q12-21;q37) t(12;12)(p13;q13) HMGA2::? t(12;12)(p13;q13) ETV6::BAZ2A t(1;3)(p36;q21) RPN1::PRDM16 t(14;21)(q22;q22) RUNX1::? der(4)t(1;4)(q11-32;q34-35) t(15;21)(q22;q22) RUNX1::? +15 or trisomy 15 (as sole autosomal abnormality) t(16;21)(q24;q22) RUNX1::CBFA2T3 t(1;6)(p36;p21) del(17p) in myeloid malignancies t(1;7)(p36;p12) IKZF1::PRDM16 inv(18)(p11q21) +19 or trisomy 19 del(1p) solely t(20;21)(q13;q22) RUNX1::? t(20;21)(q13.2;q22.12) ZFP64::RUNX1 t(2;11)(p21;q23) KMT2A::? t(2;11)(q31;p15) (MDS, AML; NUP98 and HOXD13; rare) t(2;12)(q31;p13) ETV6::? del(21)(q21q22) USP16::RUNX1 +21 or trisomy 21 t(2;8)(q12;p11) RANBP2::FGFR1 +2 or trisomy 2 t(3;11)(p25;p15) ANKRD28::NUP98 t(3;11)(q12;p15) NUP98::LNP1 t(3;16)(q21;q22) t(3;18)(q26;q11) ?::MECOM t(3;21)(q26;q11) NRIP1::MECOM t(3;4)(p21;q34) inv(3)(p24q26) ?::MECOM t(3;3)(p24;q26) ?::MECOM t(4;11)(p12;q23) KMT2A::FRYL t(4;5)(q31;q31) i(4p) in myeloid malignancies t(5;16)(q32;p13) NDE1::PDGFRB t(5;17)(q33;p11.2) SPECC1::PDGFRB t(5;17)(q33;p13) RABEP1::PDGFRB t(5;17)(q35;q21) without RARA involvement in non-M3 AML t(5;21)(q13;q22) RUNX1::? t(5;7)(q33;q11) HIP1::PDGFRB del(5q) in myeloid neoplasms del (5q) solely in Myelodysplastic syndrome t(6;12)(p21;p13) CCND3::ETV6 in lymphoid malignancies t(6;17)(p21;p13) t(6;20)(q13;q12) LMBRD1::CHD6 t(6;21)(p22;q22) RUNX1-? t(6;8)(q27;p12) FGFR1OP::FGFR1 t(6;9)(p22;q34) DEK::NUP214 t(6;9)(p22;q34) DEK::NUP214 in Childhood del(6q) inv(6)(p25q13) inv(6)(p25q13) t(7;12)(p12;q13) HMGA2 truncated -7::del(7q) in childhood -7::del(7q) in adults i(7)(q10) t(8;12)(q12;p13) t(8;13)(p11;q12) ZMYM2::FGFR1 t(8;21)(q23;q22) RUNX1::ZFPM2 t(8;9)(p22;p24) PCM1::JAK2 r(8) t(9;12)(q22;p13) ETV6::SYK Childhood myelodysplastic syndromes Classification of myelodysplastic syndromes 2015 Classification of myelodysplasic syndromes 1999 Chronic Myelomonocytic Leukemia (CMML) Congenital leukaemias Infant leukaemias Neonatal leukaemias Myelodysplastic syndrome with excess blasts Refractory anemia with excess blasts (RAEB) in 2003 Refractory anemia (RA) Refractory anemia with ringed sideroblasts (RARS) Therapy-Related Hematopoietic Neoplasia 3. Treatment Related Leukaemias (t-AML) t(10;11)(p12;q23) KMT2A::MLLT10 11p15 rearrangements (NUP98) in treatment related leukemia 11q23 rearrangements (KMT2A) in therapy related leukaemias t(11;12)(p15;q13) NUP98::HOXC11 t(11;12)(p15;q13) NUP98::HOXC13 t(11;12)(q23;q13) ::HMGA2 t(11;14)(q23;q32) KMT2A::CEP170B t(11;15)(q23;q14) KMT2A::CASC5 t(11;17)(q23;p13) KMT2A::GAS7 t(11;19)(q23;p13.1) KMT2A::ELL t(11;19)(q23;p13.3) KMT2A::MLLT1 t(11;22)(q23;q13) KMT2A::EP300 t(11;11)(q13;q23) KMT2A::ARHGEF17 12p13 rearrangements (ETV6) in treatment related leukemia t(1;21)(p22;q22) RUNX1::CLCA2 t(12;21)(q24;q22) RUNX1::? t(15;17)(q24;q21) PML::RARA t(15;17)(q22;q21) in treatment related leukemia inv(16)(p13q22) CBFB::MYH11 in treatment related leukemia t(18;21)(q21;q22) RUNX1::? t(19;21)(q13.4;q22) RUNX1 truncated 21q22 rearrangements (RUNX1) in treatment related leukemia t(2;19)(p11;p13) t(2;8)(p23;p11) KAT6A::ASXL2 t(2;9)(q12;q34) RANBP2::ABL1 t(3;11)(p21;q23) KMT2A::NCKIPSD t(3;11)(p11;p15) NUP98::POU1F1 t(3;11)(q28;q23) KMT2A::LPP t(3;11)(q25;q23) KMT2A::GMPS t(3;12)(q26;q21) ?::MECOM t(3;21)(q26;q22) RUNX1::MECOM in treatment related leukemia 3q21q26 rearrangements (RPN1::MECOM) in treatment related leukemia t(3;6)(q25;q26) ?::MECOM t(4;11)(q21;q23) KMT2A::AFF1 t(4;12)(q12;p13) CHIC2::ETV6 t(6;11)(q27;q23) KMT2A::AFDN t(8;16)(p11;p13) KAT6A::CREBBP in treatment related leukemia t(8;21)(q22;q22) RUNX1::RUNX1T1 t(8;21)(q22;q22) RUNX1::RUNX1T1 in treatment related leukemia t(9;11)(p21;q23) KMT2A::MLLT3 t(9;21)(p22;q22) t(9;22)(q34;q11) BCR::ABL1 in treatment related leukemia Acute myeloid leukemia with myelodysplasia related changes Biphenotypic Acute Leukaemia (BAL) t(X;11)(q28;p15) NUP98::HMGB3 4. Acute Myeloid Leukaemias (AML) t(10;11)(p12;q21) PICALM::MLLT10 t(10;11)(p11.2;q23) KMT2A::ABI1 t(10;11)(p12;q23) KMT2A::NEBL t(10;11)(q22;q23) KMT2A::TET1 t(10;16)(q22;p13) KAT6B::CREBBP t(10;17)(p15;q21) ZMYND11::MBTD1 +10 or trisomy 10 (solely) inv(11)(p15q22) NUP98::DDX10 t(11;11)(p15;q22) NUP98::DDX10 11q23 rearrangements (KMT2A) in de novo childhood acute myeloid leukemia t(11;12)(p15;p13) NUP98::KDM5A t(11;12)(q23;q13) KMT2A::SARNP t(11;14)(q23;q24) KMT2A::GPHN t(11;15)(q23;q14) KMT2A::ZFYVE19 t(11;16)(q23;q24) KMT2A::USP10 t(11;17)(q23;q21) ZBTB16::RARA t(11;17)(q13;q21) NUMA1::RARA t(11;17)(q23;q12) KMT2A::RARA t(11;17)(p15;p13) NUP98::PHF23 t(11;17)(q23;q12-21) KMT2A::MLLT6 t(11;17)(q23;q21) KMT2A::ACACA t(11;17)(q23;q12-21) KMT2A::LASP1 t(11;19)(q23;p13) KMT2A::SH3GL1 t(11;19)(q23;p13) KMT2A::MYO1F t(1;11)(p32;q23) KMT2A::EPS15 t(1;11)(q21;q23) KMT2A::MLLT11 t(11;21)(p14;q22) RUNX1::KIAA1549L t(11;21)(q21;q22) RUNX1::LPXN t(11;22)(q23;q11.2) KMT2A::SEPT5 t(1;12)(q25;p13) ETV6::ABL2 t(1;12)(p36;p13) ETV6::PRDM16 t(1;12)(q21;q24) t(1;16)(q12;q24) t(1;17)(q42;q21) IRF2BP2::RARA t(1;17)(p36;q21) WNT3 or NSF::PRDM16 t(1;18)(q25;q23) del(11)(q23q23) KMT2A::CBL t(11;11)(q23;q23) KMT2A::CBL del(11)(q23q23) KMT2A::ARHGEF12 inv(11)(q14q23) KMT2A::PICALM t(11;11)(q14;q23) KMT2A::PICALM t(12;17)(p11;q11) in AML t(12;19)(q13;q13) t(1;21)(p32;q22) RUNX1::? t(1;21)(p35;q22) RUNX1::YTHDF2 t(1;21)(q12;q22) RUNX1::? t(1;21)(q21;q22) RUNX1::ZNF687 t(12;21)(q12;q22) RUNX1 truncated t(12;22)(p13;q11) (AML; MN1 and ETV6; rare) t(1;22)(p13;q13) RBM15::MKL1 t(1;2)(q12;q37) in acute leukemias +13,+13 or tetrasomy 13 +13 or trisomy 13 t(1;5)(p32;q31) without TAL1 rearrangement t(16;21)(p11;q22) FUS::ERG inv(16)(p13q24) CBFA2T3::GLIS2 dic(17;20)(p11.2;q11.2) t(17;20)(q21;q11) t(17;21)(q11.2;q22) RUNX1::? t(1;7)(p36;q34) dup(17)(q12q21) STAT5B::RARA t(17;17)(q21;q21) STAT5B::RARA del(17)(q21q24) PRKAR1A::RARA t(17;17)(q21;q24) PRKAR1A::RARA t(18;21)(p11;q11) t(1;8)(p21-22;q24) t(1;8)(p22-p32;q22-q23) +18 or trisomy 18 in lymphoproliferative disorders t(1;1)(p36;p36) PRDM16::SKI t(1;1)(p36;q41) DUSP10::PRDM16 t(20;21)(q11;q22) RUNX1::NOL4L t(2;11)(q31;p15) NUP98::HOXD11 t(2;11)(q31;p15) NUP98::HOXD13 t(2;11)(q33;q23) KMT2A::ABI2 t(2;11)(q37;q23) KMT2A::SEPT2 t(2;17)(q32;q21) NABP1::RARA t(2;21)(p11;q22) RUNX1::? +22 or trisomy 22 (solely?) t(2;3)(p16;q26) BCL11A::MECOM t(2;3)(p21;q26) THADA::MECOM inv(2)(p23q13) RANBP2::ALK t(2;2)(p23;q13) RANBP2::ALK del(2)(p22p22) LTBP1::BIRC6 t(2;2)(p22;p22) LTBP1::BIRC6 t(3;11)(p24;p15) (AML; NUP98 and TOP2B; rare) t(3;11)(q13.13;q23) KMT2A::KIAA1524 t(3;17)(p25;q21) (AML; -- and RARA; rare) t(3;17)(q26;q12-21) TBL1XR1::RARA t(3;21)(p12;q22) RUNX1::? t(3;5)(p21;q32) RBM6::CSF1R t(3;5)(q21;q31) t(3;5)(q26;q31) H2AFY::MECOM t(3;5)(q26;q34) ?::MECOM t(3;7)(q26;q21) MECOM::CDK6 t(3;8)(p25;q24) t(3;8)(q21;q24) in myeloid malignancies t(3;8)(q26;q24) PVT1::MECOM del(3)(q26.2q26.3) TBL1XR1::MECOM TBL1XR1::MECOM fusion ins(3;3)(q26;q21q26) RPN1::MECOM inv(3)(q21q26) RPN1::MECOM t(3;3)(q21;q26) RPN1::MECOM inv(3)(q21q26) RPN1::MECOM t(4;11)(q35;q23) KMT2A::SORBS2 t(4;12)(q21;p13) t(4;21)(q31;q22) RUNX1::SH3D19 del(4)(q12q12) FIP1L1::PDGFRA +4 or trisomy 4 t(5;11)(q35;p15.5) NUP98::NSD1 t(5;11)(q35;q12) NSD1::FEN1 t(5;12)(p13;p13) NIPBL::ETV6 t(5;12)(q13;p13) ?::ETV6 t(5;12)(q33;p13) ERC1::PDGFRB t(5;14)(q33;q32) PDGFRB::TRIP11 t(5;14)(q35;q11) RANBP17 (or TLX3)::TRD t(5;14)(q35;q11) TRD::NKX2-5 t(5;16)(q33;q22) t(5;17)(p11;q11) t(5;17)(q11-12;q11-12) t(5;17)(q35;q21) NPM1::RARA t(5;9)(q35;q34) SQSTM1::NUP214 i(5)(p10) in acute myeloid leukemia +5 or trisomy 5 t(6;11)(q13;q23) KMT2A::SMAP1 t(6;11)(q15;q23) KMT2A::? t(6;11)(q21;q23) KMT2A::FOXO3 t(6;11)(q24.1;p15.5) NUP98::CCDC28A t(6;12)(q15;p13)::NHL (AML, T-CLD; - ; rare) t(6;12)(q22;p13) ETV6::FRK t(6;12)(q21-22;p13) (AML, B-ALL, T-ALL, CLD; FRK and ETV6 in AML; rare) t(6;14)(q25-27;q32) BCL11B::? t(6;22)(p21;q11) t(6;8)(p21;q24) MYC::SUPT3H t(7;12)(q36;p13) MNX1::ETV6 inv(14)(q11q32.1) TRA-TRD::TCL1A t(14;14)(q11;q32.1) TRA-TRD::TCL1A t(7;14)(q35;q32.1) TRB::TCL1A t(7;14)(p15;q32) t(7;14)(q22;q11) t(7;17)(q11;q21) GTF2I::RARA in APL t(7;21)(p15;q22) RUNX1::? t(7;21)(p22;q22) RUNX1::USP42 t(7;8)(q34;p11) TRIM24::FGFR1 +7 or trisomy 7 (solely) t(8;11)(p11;p15) NUP98::WHSC1L1 t(8;11)(p12;p15) ?::FGFR1 t(8;14)(q24;q32) in BPDCN der(8;17)(q10;q10) t(8;19)(p11;q13) KAT6A::? t(8;19)(p11;q13) ERVK-6::FGFR1 t(8;20)(p11;q13) KAT6A::NCOA3 t(8;21)(q24;q22) RUNX1::TRPS1 t(8;22)(p11;q13) KAT6A::EP300 i(8)(q10) in acute myeloid leukaemia inv(8)(p11q13) KAT6A::NCOA2 Isolated tetrasomy 8 in AML, MDS and MPD t(9;11)(q34;q23) FNBP1::KMT2A t(9;11)(p22;p15) NUP98::PSIP1 t(9;11)(q34;p15) NUP98::PRRX2 t(9;11)(q34;q23) KMT2A::DAB2IP t(9;12)(q34;p13) ETV6::ABL1 t(9;21)(q34;q22) RUNX1 truncated t(9;22)(q34;q11) BCR::ABL1 in AML Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Classification of acute myeloid leukemias Acute basophilic leukemia t(X;6)(p11;q23) MYB::GATA1 M0 acute myeloid leukemia (M0-AML) Acute promyelocytic leukemia (APL) Acute promyelocytic leukemia (APL) PML::RARA M3::M3v acute myeloid leukemia (AML M3/M3v) Acute Erythroid leukaemias Acute megakaryoblastic leukemia (AMegL) M7 acute myeloid leukemia (M7-AML) Systemic mast cell disease (SMCD) Mixed phenotype acute leukemia (MPAL) Monosomal karyotype (MK) in myeloid malignancies Myeloid sarcoma t(9;9)(q34;q34) SET::NUP214 Myeloid proliferations in Down syndrome t(X;10)(p10;p10) ins(11;X)(q23;q28q12) KMT2A::FLNA ins(X;11)(q28;q23q23) KMT2A::FLNA t(X;11)(q13;q23) KMT2A::FOXO4 t(X;11)(q22;q23) KMT2A::? t(X;11)(q24;q23) KMT2A::SEPT6 ins(X;11)(q26;q23q23) t(X;11)(q26;q23) t(X;17)(p11;q21) BCOR::RARA t(X;21)(q26;q22) ELF4::ERG t(X;21)(p22;q22) RUNX1::PRDX4 t(X;8)(q24;q24) 5. B-Cell Acute Lymphocytic Leukaemias (B-ALL) t(2;11)(q11;q23) KMT2A::AFF3 11q23 rearrangements (KMT2A) in childhood acute lymphoblastic leukemia t(11;14)(q24;q32) IGH::MIR125B1 t(11;19)(q23;p13.3) KMT2A::ACER1 t(11;20)(q23;q11) KMT2A::MAPRE1 t(1;14)(q21;q32) BCL9::IGH t(1;22)(q21;q11) IGL::BCL9 t(1;14)(q23;q32) (ALL, NHL, CLD; ---; rare) t(1;14)(q25;q32) IGH::LHX4 t(1;19)(q23;p13) TCF3::PBX1 t(1;19)(q22;p13.2) MEF2D::DAZAP1 t(1;19)(q22;p13.2) MEF2D::HNRNPUL1 inv(11)(q13q23) KMT2A::BTBD18 12p rearrangements (ETV6) in ALL t(12;14)(p13;q32) IGH::ETV6 t(12;17)(p13;q11) TAF15::ZNF384 t(12;17)(p13;q11-21) in ALL t(12;19)(p13;p13) TCF3::ZNF384 t(12;21)(p13;q22) ETV6::RUNX1 t(12;22)(p13;q12) EWSR1::ZNF384 t(13;19)(q14;p13) TCF3::? del(13q) in ALL t(14;17)(q32;q21) IGH::IGF2BP1 t(14;19)(q32;p13) IGH::BRD4 ? t(14;19)(q32;p13) IGH::EPOR t(14;19)(q32;q13) IGH::CEBPA t(14;19)(q32;q13) IGH::Various Partners t(14;20)(q32;q13) IGH::CEBPB inv(14)(q11q32) CEBPE::IGH t(14;14)(q11;q32) CEBPE::IGH 15q13-15 Rearrangements t(17;19)(q22;p13) TCF3::HLF t(1;9)(p13;p12) PAX5::HIPK1 t(1;9)(p34;q34) SFPQ::ABL1 t(1;9)(q24;q34) RCSD1::ABL1 inv(19)(p13q13) TCF3::TFPT t(19;19)(p13;q13) TCF3::TFPT dup(1q) in ALL inv(1)(q24q25) RCSD1::ABL2 t(1;1)(q24;q25) RCSD1::ABL2 TAL1 (1p32) deletion in lymphoid malignancies t(14;18)(q32;q21) IGH::BCL2 t(18;22)(q21;q11) IGL::BCL2 t(2;18)(p11;q21) IGK::BCL2 t(2;14)(p13-16;q32) IGH::BCL11A dup(21q) amplified (RUNX1) t(2;8)(p12;q24) IGK::MYC t(8;14)(q24;q32) IGH::MYC t(8;22)(q24;q11) IGL::MYC t(2;9)(p11;p13) PAX5::? t(2;9)(p24;p13) PAX5::KIDINS220 t(2;9)(q37;q34) INPP5D::ABL1 t(3;11)(q21;q23) KMT2A::EEFSEC dic(3;9)(p14;p13) PAX5::FOXP1 t(3;9)(p13;p13) (ALL; FOXP1 and PAX5; rare): t(3;9)(p13;q34.1) FOXP1::ABL1 ins(5;11)(q31;q13q23) KMT2A::AFF4 t(5;11)(q33;q13) NUMA1::PDGFRB a novel fusion t(5;12)(q33;p13) ATF7IP::PDGFRB t(5;14)(q31;q32) IGH::IL3 t(5;15)(p15;q11) t(5;9)(q14.1;p24) SSBP2::JAK2 del(5)(q32q33) EBF1::PDGFRB del(5q) in acute lymphoblastic leukemia (ALL) t(6;12)(q15;p13) t(6;12)(q22-23;p13) (Cell line (B-ALL); STL and ETV6; rare) t(6;14)(p22;q32) IGH::ID4 del(6q) abnormalities in lymphoid malignancies i(6)(p10) t(7;15)(q22;q14) CUX1::NUTM1 a novel fusion dic(7;9)(p11-13;p11) dic(7;9)(p11-12;p12-13) PAX5::LOC392027 t(7;9)(q11;p12) PAX5::POM121 t(7;9)(q11;p13) PAX5::ELN t(7;9)(q11.2;p13.2) PAX5::AUTS2 t(8;14)(q24;q11) TRA::MYC t(8;9)(q24;p13) ?::MYC i(8)(q10) in ALL t(9;10)(q34;q22) ZMIZ1::ABL1 dic(9;12)(p13;p13) PAX5::ETV6 dic(9;12)(p13;p12) PAX5::SLCO1B3 t(9;13)(p12;q21) PAX5::DACH1 t(9;14)(p24;q12) STRN3::JAK2 t(9;15)(p13;q24) PAX5::PML t(9;15)(p13;q24) PAX5::GOLGA6A dic(9;16)(p13;q11) PAX5::? dic(9;17)(p13;q11) PAX5::TAOK1 t(9;17)(p13;p12) PAX5::NCOR1 dic(9;18)(p13;q11) PAX5::ZNF521 dic(9;20)(p11-13;q11) PAX5::Various t(9;22)(q34;q11) BCR::ABL1 in ALL t(9;22)(p13;q13) PAX5::BRD1 Acute Lymphoblastic Leukemia with Hypereosinophilia High hyperdiploid acute lymphoblastic leukaemia Severe hypodiploid acute lymphoblastic leukaemia Acute lymphoblastic leukemia in Down syndrome Near haploid acute lymphoblastic leukaemia 9p Rearrangements in ALL del(9p) in Acute Lymphoblastic Leukemia i(9q) in ALL del(9)(p13p24) PAX5::JAK2 inv(9)(p13p24) PAX5::JAK2 t(9;9)(p13;p24) PAX5::JAK2 t(X;14)(p22;q32) or t(Y;14)(p11;q32) IGH::CRLF2 der(X)t(X;8)(q28;q11.2) t(X;9)(q21;p13) PAX5::DACH2 i(X)(p10) in male patients i(X)(q10) in male patients +X solely in ALL del(X)(p22p22) P2RY8::CRLF2 del(Y)(p11p11) P2RY8::CRLF2 6. T-Cell Acute Lymphocytic Leukaemias (T-ALL) t(10;11)(q25;p15) NUP98::ADD3 t(10;14)(q24;q11)::NHL (T-ALL; NFKB2 and TCRA-D, not rare) t(10;10)(p12;q21) CTNNA3::ARHGAP21 t(11;14)(p13;q11) TRD::LMO2 t(7;11)(q35;p13) TRB::LMO2 t(11;14)(p15;q11) TRD::LMO1 t(7;11)(q34;p15) TRB::LMO1 t(11;18)(p15;q12) NUP98::SETBP1 del(11)(p12p13) LMO2 t(1;3)(p32;p21) TCTA::TAL1 t(14;21)(q11;q22) TRA::OLIG2 t(1;5)(p32;q31) ?::TAL1 1p32 rearrangements t(1;14)(p32;q11) TRA::TAL1 t(1;7)(p32;q34) TRB::TAL1 t(1;7)(p34;q34) TRB::LCK t(1;8)(p11-13;q24) t(2;21)(q11;q22) t(3;11)(q29;p15) NUP98::IQCG t(4;11)(q21;p15) NUP98::RAP1GDS1 t(4;11)(q23;p15) NUP98::RAP1GDS1 t(4;21)(q31;q22) RUNX1::? t(5;14)(q35;q32) BCL11B::TLX3 t(5;14)(q35;q32.2) BCL11B::TLX3 and NKX2-5 t(5;17)(q13;q21) t(5;6)(q33;q23) CEP85L::PDGFRB t(5;7)(q35;q21) TLX3::CDK6 t(6;11)(q13;q12) EEF1G::OOEP t(6;7)(q23;q34) TRB::MYB and AHI1 t(10;14)(q24;q11) TLX1::TRD t(7;10)(q34;q24) TRB::HOX11 t(12;14)(p13;q11) TRA or TRD::CCND2 t(7;12)(q34;p13) TRB::CCND2 t(7;14)(p15;q11) TRD::HOXA10 t(7;14)(q34;q11) TRA::TRB t(7;14)(q34;q11) TRA::TRB t(7;19)(q34;p13) TRB::LYL1 inv(7)(p15q34) TRB::HOXA10 t(7;7)(p15;q34) TRB::HOXA10 t(7;9)(q34;q32) TRB::TAL2 t(7;9)(q34;q34) TRB::NOTCH1 t(8;12)(q13;p13) ETV6::NCOA2 t(9;14)(q34;q32) EML1::ABL1 NK cell neoplasias Pediatric T-Cell Acute Lymphoblastic Leukemia T-lineage acute lymphoblastic leukemia (T-ALL) NUP214::ABL1 fusion gene on amplified episomes Early T-cell precursor acute lymphoblastic leukemia t(X;10)(p11;p12) DDX3X::MLLT10 t(X;7)(q22;q34) IRS4::TRB 7. Non Hodgkin Lymphomas and Chronic Lymphoproliferative Diseases (NHL and CLD) Classification of B-cell non-Hodgkin's lymphomas (NHL) Classification of B-cell chronic lymphoproliferative disorders (CLD) Classification of Hodgkin lymphoma over years t(10;14)(q24;q32) (B-NHL; NFKB2 and IGH; rare) t(10;14)(q24;q32) NFKB2::IGH t(11;14)(q13;q32) IGH::CCND1 t(11;14)(q13;q32) IGH::CCND1 in multiple myeloma t(11;14)(p11;q32) t(11;14)(p13;q32) IGH::CD44 t(11;14)(q11;q32) t(11;18)(q21;q21) BIRC3::MALT1 t(11;19)(q13;p13) FSTL3::CCND1 t(1;13)(q32;q14) t(1;14)(q21;q32) t(1;22)(q21;q11) t(1;14)(p35;q32) LAPTM5::IGH t(1;14)(q21;q32) FCGR2B::IGH t(1;14)(q21;q32) FCRL4::IGH t(1;14)(q21;q32) MUC1::IGH t(1;14)(p22;q32) IGH::BCL10 t(1;2)(p22;p12) IGK::BCL10 del(11q) in non-Hodgkin's lymphoma (NHL) 1q rearrangements in multiple myeloma t(1;22)(p36;q11) IGL::PRDM16 12p rearrangements in CLL t(1;2)(q25;p23) TPM3::ALK +12 or trisomy 12 del(13q) in chronic lymphoproliferative diseases del(13q) in chronic lymphocytic leukemia del(13q) in multiple myeloma del(13q) in non-Hodgkin's lymphoma t(1;3)(q25;q27) GAS5::BCL6 t(14;15)(q32;q11) IGH::NBEAP1 t(14;16)(q32;q23) IGH::MAF t(14;18)(q32;q21) IGH::MALT1 t(14;19)(q11;q13) TRA::NECTIN2 t(14;20)(q32;q12) IGH::MAFB in Plasma Cell Myeloma t(14;22)(q32;q11) IGH::IGL Multiple Myeloma t(1;6)(p35;p25) ?::IRF4 del(17p) in non-Hodgkin's lymphoma (NHL) t(1;7)(q21;q22) t(1;1)(p36;q21) in Non Hodgkin Lymphoma t(2;11)(p23;q12.3) EEF1G::ALK t(12;14)(p13;q32) IGH::CCND2 t(12;22)(p13;q11) IGL::CCND2 t(2;12)(p12;p13) IGK::CCND2 t(14;19)(q32;q13.3) IGH::BCL3 t(19;22)(q13.3;q11) BCL3::IGL t(2;19)(p12;q13.3) IGK::BCL3 t(2;17)(p23;q23) CLTC::ALK t(2;17)(p23;q25) RNF213::ALK t(2;18)(p11;q21)IGK::BCL2 and IGK/KDSR t(2;18)(q11;q21) AFF3::BCL2 t(2;19)(p23;p13) TPM4::ALK t(2;22)(p13;q11) (NHL; REL and IgL; rare) t(2;22)(p23;q11) CLTCL1::ALK t(2;22)(p23;q11) MYH9::ALK t(2;3)(p12;q27) IGK::BCL6 t(3;14)(q27;q32) IGH::BCL6 t(3;22)(q27;q11) IGL::BCL6 t(2;3)(p23;q21) TFG::ALK t(2;5)(p23;q35) NPM1::ALK t(2;5)(p23;q35) SQSTM1::ALK t(2;6)(p12;p25) IRF4::IGK t(6;14)(p25;q32) IRF4::IGH t(6;22)(p25;q11) IRF4::IGL t(2;7)(p11;q21) IGK::CDK6 t(7;14)(q21;q11) TRA::CDK6 t(7;14)(q21;q32) IGH::CDK6 t(7;22)(q21;q11) IGL::CDK6 t(2;8)(p15;q24) BCL11A::MYC t(2;9)(p23;q33) TRAF1::ALK inv(2)(p23q35) ATIC::ALK t(3;11)(q27;q23) POU2AF1::BCL6 t(3;12)(q27;p12) LRMP::BCL6 t(3;12)(q27;p13) GAPDH::BCL6 t(3;12)(q27;q23) (NHL; BCL6 and NACA; rare) t(3;13)(q27;q14) LCP1::BCL6 t(3;14)(p14;q32) IGH::FOXP1 t(3;14)(q21;q32) t(3;16)(q27;p11) IL21R::BCL6 t(3;16)(q27;p13) CIITA::BCL6 t(3;19)(q27;q13) NAPA::BCL6 3q27 rearrangements (BCL6) in non Hodgkin lymphoma t(3;Var)(q27;Var) in non Hodgkin lymphoma t(3;4)(q27;p13) RHOH::BCL6 t(3;6)(q27;p21) SRSF3::BCL6 t(3;6)(q27;p21) PIM1::BCL6 t(3;6)(q27;p21) t(3;6)(q27;p22) HIST1H4I::BCL6 t(3;6)(q27;q14) SNHG5::BCL6 t(3;6)(q27;q15) ?::BCL6 t(3;7)(q27;p12) IKZF1::BCL6 t(3;7)(q27;q32) MIR29A::BCL6 t(3;7)(q27;q32) FRA7H::BCL6 t(3;8)(q27;q24) BCL6::MYC Polyclonal B Lymphocytosis with Binucleated Lymphocytes (PPBL) t(3;9)(q26;p23) ?::MECOM t(3;9)(q27;p13) GRHPR::BCL6 t(3;9)(q27;p24) DMRT1::BCL6 i(3)(q10) in non-Hodgkin's lymphoma (NHL) t(3;3)(q25;q27) MBNL1::BCL6 del(3)(q27q27) ST6GAL1::BCL6 t(3;3)(q27;q27) ST6GAL1::BCL6 t(3;3)(q27;q28) EIF4A2::BCL6 t(3;3)(q27;q29) TFRC::BCL6 +3 or trisomy 3 in non Hodgkin's lymphoma (NHL) t(4;12)(p16;p13) ETV6::FGFR3 t(4;14)(p16;q32) IGH::FGFR3 and WHSC1 t(4;16)(q26;p13) IL2::TNFRSF17 t(4;9)(q21.22;p24) SEC31A::JAK2 t(5;9)(q33;q22) ITK::SYK t(6;10)(q22;q24) NFKB2::ROS1 t(6;12)(q22;q24) NCOR2::ROS1 t(6;14)(p21;q32) IGH::CCND3 t(6;14)(p25.3;q11.2) TRA::IRF4 t(6;20)(q15;q11.2) BACH2::BCL2L1 t(6;7)(p25.3;q32.3) DUSP22::FRA7H t(6;8)(q11;q11) Lymphomatoid papulosis (LyP) with 6p25.3 rearrangement DUSP22 and IRF4:: del(6q) in Multiple Myeloma Del(6q) in Chronic lymphocytic leukaemia (CLL) t(7;14)(q21;q32) ERVW-1::IgH t(7;8)(p12;q24) ::MYC del(7q) in non-Hodgkin's lymphoma (NHL) t(8;12)(q24;p12) LRMP::MYC t(8;12)(q24;q22) BTG1::MYC t(8;17)(q24;q22) ???BCL3::MYC t(8;9)(q24;q13) t(9;14)(p13;q32) PAX5::IGH t(9;17)(q34;q23) ( NHL; - ; rare) Adult T-cell leukemia::lymphoma (ATLL) Primary Cutaneous CD8 Aggressive Epidermotropic Cytotoxic T Cell Lymphoma Aggressive natural killer leukemia (ANKL) Anaplastic large cell lymphoma, ALK-negative ALK -positive diffuse large B-cell lymphoma Alpha heavy chain disease Anaplastic B-cell lymphoma Anaplastic large cell lymphoma (ALCL) Angioimmunoblastic T-cell lymphoma Classification of B-cell chronic lymphoproliferative disorders (CLD) Classification of B-cell non-Hodgkin lymphomas (NHL) B-cell prolymphocytic leukemia (B-PLL) (published in 1998) B-cell Prolymphocytic Leukemia Breast implant-associated anaplastic large cell lymphoma Burkitt's lymphoma (BL) Castleman's disease Centroblastic lymphoma Classical Hodgkin lymphoma Classical Hodgkin lymphoma type PTLD Classification of Hodgkin lymphoma over years Chronic lymphocytic leukaemia (CLL) Cutaneous T-cell lymphomas Diffuse red pulp small B-cell lymphoma Disseminated Juvenile Xanthogranuloma DLBCL subtype: Extranodal lymphoma Primary DLBCL of the central nervous system (CNS) Primary cutaneous DLBCL, leg type Germinal center B-cell-like diffuse Large B-cell Lymphoma (GCB) DLBCL Diffuse large cell lymphoma Double Hit Lymphoma (DHL) Triple Hit Lymphoma (THL) EBV positive DLBCL, NOS Systemic EBV-positive T-cell lymphoma of childhood Extranodal NK::T-cell lymphoma, nasal type (ENKL) Fibroblastic Reticular Cell Tumor Fibrogenesis imperfecta ossium Florid follicular hyperplasia PTLD Follicular dendritic cell in lymphomas of follicular origin Follicular Dendritic Cell Sarcoma Follicular lymphomas of germinal center (B- or T-cell) origin Follicular lymphoma (FL) Gamma heavy chain disease Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-V) Heavy chain diseases Hepatosplenic T-cell lymphoma (HSTCL) Histiocytic Sarcoma Hodgkin lymphoma Immunoblastic lymphoma Indeterminate Dendritic Cell Tumor Infectious mononucleosis-like PTLD Interdigitating Dendritic Cell Sarcoma B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma Intestinal T-cell lymphoma Langerhans cell sarcoma Langerhans cell histiocytosis Lymphoplasmacytic lymphoma Lymphocyte depletion classical Hodgkin lymphoma Lymphoepithelioid lymphoma HIV-associated lymphomas Lymphocyte-rich classical Hodgkin lymphoma Mucosa-associated lymphoid tissue (MALT) lymphoma Mantle cell lymphoma Marginal Zone B-cell lymphoma Mediastinal Gray Zone Lymphoma Mixed cellularity classical Hodgkin lymphoma (MCcHL) Multiple myeloma (published in 2004) Monomorphic PTLD (B- and T::NK-cell types) Mu heavy chain disease Mycosis fungoides::Sezary's syndrome Nasal T cell lymphoma (published in 2008) Nodal marginal zone lymphoma (NMZL) Nodular lymphocyte-predominant Hodgkin lymphoma Nodular sclerosis classical Hodgkin lymphoma (NScHL) Ocular adnexal marginal zone lymphoma (OAMZL) Pediatric-type Follicular Lymphoma Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) Plasmablastic lymphoma (PBL) Plasma cell leukemia (PCL) Polymorphic PTLD Primary cutaneous CD30+ anaplastic large cell lymphoma Primary Cutaneous B-Cell Lymphomas Primary gastric lymphoma Primary mediastinal B-cell lymphoma (PMBL) Small lymphocytic lymphoma Splenic lymphoma with villous lymphocytes (SLVL) in 2005 Subcutaneous panniculitis-like T-cell lymphoma Classification of T-Cell disorders T-cell::histiocyte rich large B-cell lymphoma T-cell large granular lymphocyte leukaemia T-cell prolymphocytic leukemia (T-PLL) Histiocyte-rich B-cell lymphoma Waldenstrom's macroglobulinemia (published in 2002) Waldenstrom macroglobulinemia Plasmacytoma (Solitary bone plasmacytoma, extramedullary plasmacytoma) t(X;11)(q21;q23) BRWD3::ARHGAP20 t(X;14)(p11.4;q32.33) IGH::GPR34 t(X;14)(q28;q11.2) TRA-TRD::MTCP1 t(X;7)(q28;q34) TRB::MTCP1 t(X;2)(q11;p23) MSN::ALK +X solely in lymphomas 8. Not Classified P2RY8::ZBED1 (Xp22) PAGE2B::ALAS2 (Xp11) t(X;X)(p11;q13) NONO::TFE3 t(X;X)(p11;q13) TFE3::NONO t(X;X)(q21;q25) STAG2::ATRX ARL13A::TRMT2B (Xq22) t(X;X)(q25;q26) STAG2::GPR119 t(X;11)(q26;q23) KMT2A::CT45A3 t(X;12)(q24;q23) CHST11::ATP1B4 t(X;12)(q25;p13) OLR1::XIAP t(X;12)(q25;p13) TMEM52B::XIAP t(X;12)(q25;p13) XIAP::OLR1 t(X;14)(q22;q32) RNA28S5::BCL11B t(X;14)(q28;q11) TRA::MTCP1 t(X;15)(p11;q25) MESD::CASK t(X;17)(q22;q25) COG1::RNA28S5 t(X;17)(q25;q11) KSR1::TENM1 t(X;2)(q13;p21) NONO::ZFP36L2 t(X;2)(q22;p11) IGKV3-20::RNA28S5 t(X;6)(p11;q21) CD24::RBM3 t(X;6)(q27;q23) FGF13::SGK1 t(X;7)(q13;p15) MED12::HOXA9 t(X;7)(q22;q34) TRB::IRS4 t(X;7)(q25;p21) STAG2::BZW2 t(X;8)(q25;q22) VPS13B::STAG2 t(X;9)(p11;p13) PAX5::BCOR t(X;9)(p22;p13) P2RY8::PAX5 t(X;9)(p22;p13) PAX5::P2RY8 t(X;9)(p22;p24) CD99::JAK2 t(X;9)(p22;p24) OFD1::JAK2 t(X;9)(q24;p13) PAX5::RHOXF2 del(X)(p22p22) CSF2RA::CRLF2 t(Y;12)(q11;q24) KDM2B::UTY t(10;10)(p11;p12) ZEB1::BMI1 t(10;10)(p12;p13) MLLT10::FAM171A1 PARG::BMS1 (10q11) TIMM23B::LINC00843 (10q11) t(10;10)(q23;q24) LINC00502::TLX1 t(10;10)(q23;q24) MGEA5::RNLS C10orf76::PSD (10q24) DNTT::BLNK (10q24) LCOR::HPSE2 (10q24) t(10;11)(p12;q13) MLLT10::RNF169 t(10;11)(p12;q23) MLLT10::CEP164 t(10;11)(p12;q23) MLLT10::PPP2R1B t(10;11)(q23;p15) NUP98::HHEX t(10;12)(p12;q21) MLLT10::CAPS2 t(10;12)(p12;q21) NAP1L1::MLLT10 t(10;12)(p12;q24) APBB1IP::SCARB1 t(10;12)(q24;p13) PDZD7::ETV6 t(10;13)(q21;q14) CDK1::DGKH t(10;14)(p12;q32) IGH::BMI1 t(10;14)(q24;q11) TLX1NB::TRDC t(10;14)(q24;q11) TLX1NB::TRD t(10;14)(q24;q11) TLX1::TRA t(10;17)(p15;q21) MBTD1::ZMYND11 t(10;17)(q22;q25) ASCC1::MAFG t(10;17)(q26;q22) CFAP46::MSI2 t(10;19)(p11;p13) KDM4B::CUL2 t(10;19)(p12;p13) MAP2K2::MLLT10 t(10;19)(q24;p13) NFKB2::TYK2 t(10;20)(q23;q13) DPM1::GRID1 t(10;20)(q23;q13) GRID1::DPM1 t(10;21)(q22;q22) NDST2::RUNX1 t(10;21)(q22;q22) RUNX1::KCNMA1 t(10;21)(q23;q22) RUNX1::LIPA t(10;21)(q24;q22) RUNX1::PDZD7 t(10;22)(q11;q11) BCR::RET t(1;10)(q21;p11) NRP1::ANP32E ACCS::EXT2 (11p11) t(11;11)(p11;q23) PTPRJ::C2CD2L t(11;11)(p13;q24) ARHGAP32::CAPRIN1 t(11;11)(p15;q23) KMT2A::AP2A2 t(11;11)(p15;q23) NUP98::CADM1 NXF1::GANAB (11q12) t(11;11)(q12;q23) KMT2A::PRPF19 t(11;11)(q12;q23) YPEL4::KMT2A RTN3::STIP1 (11q13) t(11;11)(q13;q14) PPP6R3::INTS4 t(11;11)(q13;q23) KMT2A::C2CD3 CTSC::RAB38 (11q14) t(11;11)(q14;q23) TENM4::CADM1 t(11;11)(q22;q23) C2CD2L::DDX10 C11orf1::SIK3 (11q23) DDX6::FOXR1 (11q23) KMT2A::BCL9L (11q23) KMT2A::BUD13 (11q23) KMT2A::CEP164 (11q23) KMT2A::USP2 (11q23) PPP2R1B::SIK3 (11q23) RNF214::KMT2A (11q23) SIDT2::TAGLN (11q23) SIK3::C11orf1 (11q23) t(11;11)(q23;q24) KMT2A::DCPS t(11;11)(q24;q23) TIRAP::KMT2A t(11;12)(p15;q13) NUP98::HOXC13 t(11;12)(p15;q13) NUP98::RARG t(11;12)(q12;p13) ETV6::LPXN t(11;12)(q23;p12) KRAS::KMT2A t(11;13)(q23;q14) KMT2A::ZC3H13 t(11;14)(p13;q11) TRA::LMO2 t(11;14)(p15;q11) LMO1::TRA t(11;14)(q13;q24) ZFP36L1::EHD1 t(11;14)(q23;q24) RAD51B::KMT2A t(11;14)(q23;q32) IGH::DDX6 t(11;14)(q23;q32) PAFAH1B2::IGH t(11;14)(q23;q32) PCSK7::IGH t(11;14)(q23;q32) IGH::PCSK7 t(11;14)(q23;q32) IGH::PAFAH1B2 t(11;15)(q23;q14):t(11;15)(q23;q15) KMT2A::KNL1 t(11;15)(q23;q21) KMT2A::TCF12 t(11;15)(q23;q25) KMT2A::AKAP13 t(11;16)(p11;p13) PHF21A::GLIS2 t(11;16)(q23;p13) KMT2A::MYH11 t(11;16)(q23;q12) KMT2A::NKD1 t(11;17)(p15;q22) MPO::FAR1 t(11;17)(p15;q24) NUP98::BPTF t(11;17)(q23;p11) KMT2A::TOP3A t(11;18)(q23;q21) KMT2A::ME2 t(11;19)(q23;p13) H2AFX::WDR18 t(11;19)(q23;p13) KMT2A::SUGP2 t(11;19)(q23;p13) KMT2A::VAV1 t(11;19)(q23;p13) WDR18::H2AFX t(11;19)(q23;q13) KMT2A::ACTN4 t(11;19)(q23;q13) CEP164::EMP3 t(11;19)(q23;q13) ZNF585B::C2CD2L t(11;19)(q24;p13) TCF3::FLI1 t(1;11)(p13;q23) KMT2A::SLC25A24 t(1;11)(p34;p13) FOXJ3::LMO2 t(1;11)(p35;q14) RCC1::PICALM t(1;11)(p36;p11) STMN1::SPI1 t(1;11)(q42;q13) CCND1::CDC42BPA t(1;11)(q44;q24) ZNF124::PUS3 t(11;20)(q13;q13) ZMYND8::RELA t(11;21)(q13;q22) PDE9A::MUS81 t(11;22)(q24;q12) EWSR1::FLI1 t(11;22)(q24;q12) MN1::FLI1 t(1;12)(q22;p13) FOXJ2::MEF2D t(1;12)(q22;p13) MEF2D::FOXJ2 t(1;12)(q22;q13) MEF2D::STAT6 t(1;12)(q25;p13) ETV6::QSOX1 t(1;12)(q42;p13) ETV6::NID1 t(1;13)(p36;q14) PAX3::FOXO1 t(1;13)(p36;q14) PAX7::FOXO1 t(1;14)(p13;q32) IGH::BCAS2 t(1;14)(p33;q11) TAL1::TRA t(1;14)(p33;q11) TRD::TAL1 t(1;14)(p34;q24) SFPQ::ZFP36L1 t(1;14)(q43;q24) CEP170::RAD51B t(1;16)(p31;q24) NFIA::CBFA2T3 t(1;17)(p31;p11) NCOR1::NFIA t(1;17)(p34;p13) SLC2A4::ERMAP t(1;17)(p36;q25) METRNL::SKI t(1;17)(q23;q12) IKZF3::ETV3 t(1;18)(q22;q11) MEF2D::SS18 t(1;18)(q22;q11) SS18::MEF2D t(1;19)(p34;p13) PABPC4::TYK2 t(1;19)(q22;p13) DAZAP1::MEF2D del(11)(q24) KMT2A::TIRAP t(1;1)(p12;p13) DDX20::TBX15 CTBS::GNG5 (1p22) t(1;1)(p33;q25) DHX09::TAL1 t(1;1)(p33;q25) DHX9::TAL1 t(1;1)(p33;q42) GNPAT::TAL1 PPCS::CCDC30 (1p34) CDK11B::SLC35E2 (1p36) CRTC2::CREB3L4 (1q21) NOTCH2NL::NBPF10 (1q21) t(1;1)(q21;q22) MEF2D::BCL9 t(1;1)(q21;q23) B4GALT3::TPM3 VANGL2::UFC1 (1q23) t(1;1)(q23;q24) DCAF8::DNM3 COP1::TNFSF18 (1q25) DHX09::NPL (1q25) LHX4::BRINP2 (1q25) DHX9::NPL (1q25) GUK1::ARF1 (1q42) t(1;1)(q42;q43) NVL::FMN2 t(1;20)(q25;q13) RABGAP1L::TUBB1 t(1;20)(q32;q11) DNMT3B::MDM4 t(1;20)(q32;q11) MDM4::DNMT3B t(12;12)(p12;p13) ETV6::PTPRO ETV6::BCL2L14 (12p13) ETV6::BORCS5 (12p13) ETV6::CDKN1B (12p13) VAMP1::CD27-AS1 (12p13) t(12;12)(p13;q13) ETV6::PMEL t(12;12)(p13;q24) ETV6::CDK2AP1 PRIM1::NACA (12q13) ACAD10::MAPKAPK5 (12q24) NCOR2::SCARB1 (12q24) NOC4L::FBRSL1 (12q24) POLE::FBRSL1 (12q24) ZCCHC8::RSRC2 (12q24) t(12;14)(p12;q32) IGH::SOX5 TRDREC::C12orf42 () t(12;14)(q23;q32) IGH::CHST11 t(12;14)(q24;q11) MYH6::GOLGA3 t(12;15)(p13;q22) ETV6::RNU6-19P t(12;16)(p13;p13) CREBBP::ZNF384 t(12;16)(p13;p13) ETV6::CREBBP t(12;16)(p13;p13) ZNF384::CREBBP t(12;17)(p11;q25) SINHCAF::SEPT9 t(12;17)(p13;q12) ING4::C17orf50 t(12;17)(p13;q12) SYNRG::ZNF384 t(12;17)(p13;q21) ETV6::RARA t(12;17)(q24;q11) BRAP::BLMH t(12;19)(p13;p13) NOP2::TCF3 t(12;19)(p13;p13) PLK5::ATN1 t(12;19)(q24;p13) BCL7A::DAZAP1 t(1;21)(p32;q22) RUNX1::NDC1 t(12;20)(q14;q11) HM13::TSPAN31 t(12;21)(p11;q22) RUNX1::PTHLH t(12;21)(p13;q22) PDE9A::VWF t(12;21)(p13;q22) RUNX1::DDX47 t(12;21)(q12;q22) RUNX1::CPNE8 t(12;21)(q21;q22) RUNX1::KRR1 t(12;22)(p13;q12) ETV6::EMID1 t(12;22)(p13;q13) EP300::ZNF384 t(12;22)(p13;q13) LPAR5::EP300 t(12;22)(q14;q13) HMGA2::EFCAB6 del(12)(q13q13) DHH::RHEBL1 dup(12)(q21q21) RAB21::TBC1D15 dup(12)(q24q24) VPS33A::MPHOSPH9 inv(12)(p13p13) IQSEC3::KDM5A inv(12)(q13q13) NAB2::STAT6 inv(12)(q24q24) IFT81::HECTD4 t(1;2)(p34;p21) SFPQ::ZFP36L2 FLT3::FLT3 (13q12) ZMYM2::FLT3 (13q12) ZMYM5::PSPC1 (13q12) EEF1DP3::FRY (13q13) ARL11::RNASEH2B (13q14) ELF1::FOXO1 (13q14) ITM2B::RB1 (13q14) LPAR6::ITM2B (13q14) RB1::FNDC3A (13q14) RB1::WDFY2 (13q14) CLN5::FBXL3 (13q22) t(13;14)(q12;q32) TRIP11::FLT3 t(13;21)(q32;q22) RUNX1::UGGT2 del(13)(q14q14) CCDC122::VPS36 HNRNPC::ZNF219 (14q11) ZNF219::HNRNPC (14q11) t(14;14)(q11;q13) NKX2-1-AS1::TRD t(14;14)(q11;q13) NKX2-1::TRA t(14;14)(q11;q13) SFTA3::TRDC t(14;14)(q11;q13) TRA::NKX2-1 t(14;14)(q11;q32) IGH::CEBPE inv(14)(q11q32):t(14;14)(q11;q32) IGH::TRA t(14;14)(q11;q32) TRA::TCL1A t(14;14)(q13;q31) NKX2-1::DIO2 t(14;14)(q13;q32) NKX2-1::BCL11B NIN::TMX1 (14q22) t(14;14)(q22;q23) PELI2::C14orf39 t(14;14)(q22;q32) NIN::UNC79 C14orf37::ARID4A (14q23) PRKCH::C14orf37 (14q23) t(14;14)(q23;q31) ACTR10::GALC t(14;14)(q23;q32) PPP2R5C::SLC38A6 t(14;14)(q23;q32) TTC7B::SYNE2 SUSD6::RBM25 (14q24) VTI1B::RDH11 (14q24) PLD4::AHNAK2 (14q32) t(14;15)(q11;q14) ACIN1::NUTM1 t(14;15)(q23;q14) ARID4A::AVEN t(14;15)(q32;q25) IGH::BCL2A1 t(14;16)(q11;p13) USP7::TRA t(14;16)(q32;q24) IGH::CBFA2T3 t(14;16)(q32;q24) IGH::IRF8 t(14;17)(q32;p13) IGH::TNFSF13 t(14;18)(q32;q12) IGH::NOL4 t(14;18)(q32;q21) BCL2::IGHG1 t(14;19)(q23;q13) UBA2::PPP1R36 t(14;19)(q32;q13) IGH::BRD4 t(14;19)(q32;q13) IGH::CEBPG t(14;19)(q32;q13) IGH::SPIB del(14)(q24q32) ZFP36L1::IGH inv(14)(q11q32) TRA-D::IGH inv(14)(q11q32) BCL11B::TRD t(1;4)(p34;p16) THRAP3::SH3BP2 INO80::EXD1 (15q15) WDR76::SERF2 (15q15) PRC1::KIF7 (15q26) t(15;16)(q21;p13) CIITA::C15orf65 t(15;16)(q21;p13) CREBBP::TRIM69 t(15;17)(q14;q24) BPTF::NUTM1 t(15;17)(q15;q11) WSB1::HYPK t(15;19)(q21;p13) COPS2::FAM129C t(15;19)(q21;p13) FAM129C::COPS2 t(15;21)(q21;q22) RUNX1::TCF12 t(15;21)(q24;q22) RUNX1::SIN3A t(15;21)(q24;q22) RUNX1::UBL7 t(15;21)(q26;q22) RUNX1::SV2B t(1;5)(p36;q21) CHD1::MTOR t(1;5)(p36;q21) MTOR::CHD1 t(1;5)(q21;q32) TPM3::PDGFRB t(1;5)(q22;q33) MEF2D::CSF1R t(1;5)(q31;q15) CDC73::FAM172A t(1;5)(q31;q15) FAM172A::CDC73 t(16;16)(p11;p13) SETD1A::NLRC3 CIITA::??? (16p13) CIITA::RMI2 (16p13) CIITA::SNX29 (16p13) CRAMP1::CLCN7 (16p13) CREBBP::DEXI (16p13) CREBBP::DNAJA3 (16p13) CREBBP::MEFV (16p13) DNAJA3::CREBBP (16p13) TRAF7::WDR24 (16p13) TSC2::ATP6V0C (16p13) t(16;16)(p13;q22) ABCC6::C16orf70 CENPT::NUTF2 (16q22) CTCF::SLC7A6 (16q22) NFATC3::PLA2G15 (16q22) ANKRD11::SPG7 (16q24) CBFA2T3::ACSF3 (16q24) t(16;17)(q22;p11) CA7::USP22 t(16;17)(q22;p11) USP22::CA7 t(16;20)(q24;p12) CDS2::ANKRD11 t(16;21)(q23;q22) RUNX1::MLYCD t(16;22)(q24;q13) PIM3::SLC7A5 del(16)(q22q22) CTCF::PARD6A dup(16)(q24q24) USP10::ATP2C2 GOSR1::ZNF207 (17q11) NF1::LRRC37B (17q11) NF1::PSMD11 (17q11) t(17;17)(q11;q21) WSB1::NBR1 DHX08::ETV4 (17q21) KANSL1::ARL17A (17q21) KANSL1::ARL17B (17q21) SGCA::PPP1R9B (17q21) STAT5B::STAT3 (17q21) DHX8::ETV4 (17q21) t(17;17)(q21;q23) KPNB1::ACE CSNK1D::METRNL (17q25) RNF213::SLC26A11 (17q25) TBC1D16::RNF213 (17q25) t(17;19)(p13;p13) POLR2A::FBN3 t(17;19)(p13;p13) SLC35G6::FBN3 t(17;19)(p13;p13) TNK1::ZBTB7A t(17;19)(p13;p13) ZBTB7A::TNK1 t(17;19)(q22;q13) MPO::ZNF296 t(17;19)(q25;p13) TPM4::METRNL t(17;20)(p13;p12) RPL26::ESF1 t(17;21)(q21;q22) RUNX1::FAM117A t(17;22)(q21;q12) EWSR1::HOXB8 t(17;22)(q21;q13) COL1A1::PDGFB t(17;22)(q25;q13) PIM3::METRNL dup(17)(p11q11) GIT1::SHMT1 t(1;7)(p35;p15) PUM1::HOXA11 t(1;7)(q25;q34) ZC3HAV1::ABL2 t(1;7)(q42;q31) ARID4B::ING3 t(18;18)(p11;q23) MBP::TGIF1 SMAD2::ZBTB7C (18q21) t(18;19)(q21;q13) LILRA2::CCBE1 t(18;20)(p11;q13) LDLRAD4::PHACTR3 t(18;21)(q22;q22) RUNX1::ZADH2 dup(18)(p11p11) YES1::ENOSF1 t(1;8)(q25;p11) ANKRD45::HOOK3 t(1;8)(q31;p11) TPR::FGFR1 t(19;19)(p12;p13) ZNF430::TYK2 DOCK6::CCDC130 (19p13) MKNK2::RNF126 (19p13) OAZ1::RNF126 (19p13) PALM::NCLN (19p13) PIAS4::ZBTB7A (19p13) PTBP1::TMEM259 (19p13) SMARCA4::DHPS (19p13) SMARCA4::TYK2 (19p13) t(19;19)(p13;q13) PRMT1::TLE6 FLT3LG::RPS11 (19q13) PLAUR::EXOC3L2 (19q13) PLAUR::MARK4 (19q13) PPP1R12C::CIC (19q13) PPP1R37::PPP6R1 (19q13) RPS11::FLT3LG (19q13) TGFB1::TMEM91 (19q13) t(19;21)(p13;q22) MAP2K7::PRDM15 inv(19)(p13p13) GNG7::SCAMP4 inv(19)(p13p13) SPPL2B::POLR2E inv(19)(p13p13) ZNRF4::AP3D1 inv(19)(q13q13) CACNG6::ZNF320 t(1;9)(p32;p13) PAX5::DMRTA2 t(1;9)(p34;q34) CSF3R::SPTAN1 t(1;9)(p35;p24) SMARCA2::ZNF362 t(1;9)(p35;p24) ZNF362::SMARCA2 t(1;9)(p36;q32) UBR4::ZFP37 t(1;9)(q21;p24) JAK2::TPM3 t(1;9)(q21;p24) TPM3::JAK2 t(1;9)(q31;p13) DENND1B::ZCCHC7 del(1)(q25q25) RABGAP1L::ZBTB37 del(1)(q42) ESRRG::ACBD3 inv(1)(q32q42) ARID4B::RPS6KC1 BCL2L1::TTLL9 (20q11) ITCH::RPRD1B (20q11) POFUT1::HCK (20q11) PABPC1L::YWHAB (20q13) dup(20)(p13p13) TMC2::PTPRA t(2;10)(p15;p12) XPO1::MLLT10 t(2;10)(p23;p11) EPC1::ASXL2 t(2;10)(q14;q21) JMJD1C::TSN t(2;11)(q11;q23) KMT2A::FER1L5 t(2;11)(q22;q21) CXCR4::MAML2 t(2;11)(q33;q13) SF1::SF3B1 RBM11::LIPI (21q11) t(21;21)(q21;q22) USP25::TRAPPC10 BRWD1::ETS2 (21q22) ERG::DYRK1A (21q22) ETS2::ERG (21q22) IFNGR2::GART (21q22) ITSN1::KCNE2 (21q22) RUNX1::DSCAM (21q22) RUNX1::DYRK1A (21q22) WDR4::PDE9A (21q22) t(21;22)(q22;q11) CABIN1::TRAPPC10 t(2;12)(p16;p13) MSH6::ETV6 t(2;12)(q33;p13) ETV6::INO80D t(2;13)(q36;q14) PAX3::FOXO1 t(2;14)(p21;q11) ZFP36L2::TRA t(2;14)(p24;q32) IGH::MYCN t(2;14)(q22;q32) IGH::ZEB2 t(2;14)(q22;q32) ZEB2::BCL11B t(2;14)(q34;q32) IKZF2::BCL11B t(2;18)(p16;q11) KCTD1::SPTBN1 t(2;20)(p25;q11) TMEM18::ASXL1 t(2;21)(q11;q22) RUNX1::AFF3 DDTL::CABIN1 (22q11) C22orf34::BRD1 (22q13) C22orf34::ZBED4 (22q13) EP300::EP300 (22q13) PIM3::BRD1 (22q13) PIM3::SCO2 (22q13) t(2;22)(p13;q11) REL::IGL t(2;22)(p16;q11) IGL::REL t(2;2)(p11;p25) RSAD2::ELMOD3 NDUFAF7::PRKD3 (2p22) YPEL5::PPP1CB (2p23) ASXL2::PFN4 (2p23) PPP1CB::YPEL5 (2p23) t(2;2)(p24;p25) RNF144A::LAPTM4A GREB1::E2F6 (2p25) CNNM3::ANKRD23 (2q11) t(2;2)(q11;q22) MGAT4A::CXCR4 MGAT5::GPR39 (2q21) ZEB2::CXCR4 (2q22) t(2;3)(p15;p26) XPO1::BHLHE40 t(2;3)(p16;p25) BCL11A::GRIP2 t(2;3)(q33;q26) FAM117B::SEC62 t(2;4)(p23;q21) SEC31A::ALK t(2;4)(q31;q21) BMP2K::HOXD10 t(2;5)(q37;p13) HDAC4::GHR t(2;6)(p11;q25) IGK::ZC3H12D t(2;6)(p12;q24) UTRN::POLE4 t(2;6)(p22;q22) GALM::HDDC2 t(2;7)(p14;p15) PLEK::HOXA11-AS t(2;7)(p15;p22) XPO1::TNRC18 t(2;7)(q22;p12) IKZF1::ZEB2 t(2;7)(q35;q21) GTPBP10::BARD1 t(2;8)(p11;q21) IGK::TPD52 t(2;8)(p11;q24) IGK::PVT1 t(2;8)(q37;p11) LRRFIP1::FGFR1 t(2;9)(p11;p21) CDKN2A::IGK t(2;9)(q33;q22) ERCC6L2::SF3B1 inv(2)(p21p23) EML4::ALK t(3;10)(q27;p15) BCL6::FBXO18 t(3;11)(p13;q22) FOXP1::BIRC3 t(3;11)(p21;q23) KMT2A::DCP1A t(3;11)(p21;q23) KMT2A::SACM1L t(3;11)(p24;p15) NUP98::TOP2B t(3;11)(q13;q23) KMT2A::CIP2A t(3;11)(q25;p13) MBNL1::LMO2 t(3;12)(p22;p13) ETV6::CTNNB1 t(3;12)(p26;q24) KSR2::SETMAR t(3;12)(q12;p13) SENP7::ETV6 t(3;13)(q13;q12) GOLGB1::FLT3 t(3;17)(p21;q21) SMARCC1::CDK5RAP3 t(3;18)(p21;q21) MAP4::MALT1 t(3;18)(p21;q21) MALT1::MAP4 t(3;19)(p24;p13) TGFBR2::ZBTB7A t(3;19)(q27;p13) BCL6::C3 t(3;20)(q26;q11) TBL1XR1::C20orf24 t(3;21)(q22;q22) RYK::ATP5PO t(3;21)(q26;q22) RUNX1::RPL22P1 NCKIPSD::CELSR3 (3p21) SETD2::CCDC12 (3p21) UQCRC1::ANO10 (3p21) BRK1::VHL (3p25) HACL1::COLQ (3p25) RAF1::TMEM40 (3p25) dup(3)(q12q12):t(3;3)(q12;q12) ADGRG7::TFG TFG::ADGRG7 (3q12) t(3;3)(q22;q26) MSL2::TBL1XR1 t(3;3)(q23;q26) TBL1XR1::COPB2 t(3;3)(q26;q21) LINC01565::MECOM inv(3)(q21q26):t(3;3)(q21;q26):t(3;3)(q26;q21) GATA2::MECOM FNDC3B::MECOM (3q26) FXR1::TBL1XR1 (3q26) t(3;4)(q27;p15) DGKG::BST1 t(3;5)(p22;q32) GOLGA4::PDGFRB t(3;5)(q13;q32) GOLGB1::PDGFRB t(3;5)(q26;q32) TBL1XR1::CSF1R t(3;7)(p24;p15) HOTTIP::SATB1 t(3;7)(p25;p12) IKZF1::SETD5 t(3;7)(p25;p12) SETD5::IKZF1 t(3;7)(q21;p15) GATA2::HOXA10 t(3;7)(q21;p15) GATA2::HOXA9 t(3;7)(q26;q34) MECOM::TCRB1 t(3;8)(p24;q24) RFTN1::PVT1 t(3;8)(q27;q13) BCL6::MYBL1 t(3;9)(p22;q34) VILL::ABCA2 t(3;9)(q25;p13) MBNL1::PAX5 t(3;9)(q25;p13) PAX5::MBNL1 t(3;9)(q25;q31) KPNA4::PALM2 t(3;9)(q25;q34) MBNL1::ABL1 del(3)(q27):del(3)(q27q28) LPP::BCL6 inv(3)(p24p24) CMC1::SLC4A7 inv(3)(q26q28) TBL1XR1::TP63 inv(3)(q26q28) TP63::TBL1XR1 t(4;10)(q35;q26) DUX4::FRG2B ins(4;11)(q21;q23q23) AFF1::DSCAML1 ins(4;11)(q21;q23q23) AFF1::FXYD6 ins(4;11)(q21;q23q23) ATG16L2::KMT2A t(4;11)(p14;q23) KMT2A::PDS5A t(4;11)(q12;q23) KMT2A::USP46 t(4;11)(q21;q23) KMT2A::SEPT11 t(4;11)(q21;q23) AFF1::CCDC84 AFF1::PBX1 () AFF1::RABGAP1L () t(4;12)(q21;p13) BMP2K::ZNF384 t(4;12)(q21;q13) KMT2D::SEC31A t(4;14)(q21;q24) AFF1::RAD51B t(4;14)(q35;q32) DUX4::IGH t(4;14)(q35;q32) IGH::DUX4 t(4;21)(q28;q22) RCAN1::SPRY1 t(4;21)(q35;q22) DUX4::ERG t(4;21)(q35;q22) ERG::DUX4 t(4;22)(p16;q11) IGL::FGFR3 FGFRL1::CTBP1 (4p16) MAEA::CTBP1 (4p16) UVSSA::MAEA (4p16) t(4;4)(q21;q31) MAML3::CCNG2 HERC3::FAM13A-AS1 (4q22) t(4;4)(q26;q35) DUX4::CEP170P1 LRBA::SH3D19 (4q31) t(4;6)(q25;p21) LEF1::TAF8 t(4;7)(p15;p12) STIM2::IKZF1 t(4;7)(q13;q22) CUX1::AFP t(4;9)(q12;q33) CNTRL::KIT t(4;9)(q13;q34) CENPC::ABL1 inv(4)(q32q32) FAM198B::TMEM144 t(5;10)(q35;p12) HNRNPH1::MLLT10 t(5;11)(q11;q23) MTREX::SIK3 t(5;11)(q12;q23) CENPK::KMT2A t(5;11)(q14;q23) MEF2C::KMT2A t(5;11)(q23;q23) KMT2A::PRRC1 t(5;11)(q31;p11) TCF7::SPI1 t(5;11)(q31;q23) KMT2A::MATR3 t(5;11)(q33;q23) KMT2A::CCNJL t(5;11)(q35;p15) STIM1::NSD1 t(5;12)(q12;p13) ZNF384::RNF180 t(5;12)(q31;q24) KDM2B::AFF4 t(5;12)(q32;q13) BIN2::PDGFRB t(5;12)(q32;q23) SART3::PDGFRB t(5;12)(q33;p13) ETV6::EBF1 t(5;12)(q35;q14) ATP6V0E1::USP15 t(5;14)(p15;q32) IGH::TERT t(5;14)(q22;q23) DCP2::HIF1A t(5;14)(q22;q32) IGH::DCP2 t(5;14)(q33;q32) IGH::EBF1 t(5;14)(q35;q11) TRD::RANBP17 t(5;14)(q35;q11) TRD::TLX3 t(5;14)(q35;q32) BCL11B::NKX2-5 t(5;14)(q35;q32) CREBRF::AK7 t(5;14)(q35;q32) LMAN2::PAPOLA t(5;15)(p15;q14) BRD9::NUTM1 t(5;15)(q12;q25) RNF180::AKAP13 t(5;16)(q11;q21) MAP3K1::CSNK2A2 t(5;16)(q33;p13) HBA1::CD74 t(5;17)(p13;q21) NIPBL::HOXB9 t(5;17)(q32;p11) MPRIP::PDGFRB t(5;17)(q32;q11) MYO18A::PDGFRB PDGFRB::MYO18A () t(5;18)(q33;p11) PTPN2::UBLCP1 t(5;19)(q35;p13) NPM1::TYK2 t(5;20)(q32;p11) DTD1::PDGFRB t(5;20)(q32;p11) PDGFRB::DTD1 t(5;20)(q32;q13) ZMYND8::PDGFRB t(5;21)(q21;q22) CHD1::RUNX1 t(5;21)(q23;q22) RUNX1::ADAMTS19 t(5;21)(q23;q22) RUNX1::PRRC1 t(5;21)(q35;q22) HNRNPH1::ERG PRKAA1::TTC33 (5p13) t(5;5)(q14;q21) SSBP2::FER t(5;5)(q14;q32) SSBP2::CSF1R t(5;5)(q14;q33) CLINT1::MEF2C HARS2::ZMAT2 (5q31) SKP1::AFF4 (5q31) YIPF5::NR3C1 (5q31) t(5;5)(q32;q33) TNIP1::PDGFRB t(5;5)(q32;q33) CD74::PDGFRB LMAN2::NSD1 (5q35) t(5;6)(q13;q23) MYB::BDP1 t(5;7)(p13;p15) NIPBL::HOXA9 t(5;7)(p13;q34) IL7R::TRBC2 t(5;7)(q14;q32) EDIL3::MKLN1 t(5;7)(q31;q34) FCHSD1::BRAF t(5;8)(q35;p11) FGFR1::SQSTM1 t(5;8)(q35;p11) SQSTM1::FGFR1 t(5;9)(q23;q34) SNX2::ABL1 t(5;9)(q33;p24) EBF1::JAK2 t(5;9)(q33;p24) JAK2::EBF1 t(6;10)(q27;q11) FGFR1OP::RET t(6;10)(q27;q11) FGFR1OP::RET t(6;11)(q15;p15) BACH2::ZDHHC13 t(6;11)(q15;q23) KMT2A::CASP8AP2 t(6;11)(q23;q12) FAM111A::MYB t(6;11)(q23;q23) KMT2A::MAP3K5 t(6;11)(q27;q23) AFDN::KMT2A STL::ETV6 () t(6;12)(q22;p13) ETV6::RNF217 t(6;12)(q25;p13) ARID1B::ZNF384 t(6;12)(q25;q13) ARF3::TAB2 t(6;14)(p25;q32) IGH::IRF4 t(6;14)(q22;q11) TRA::CEP85L t(6;14)(q23;q24) ENTPD5::AHI1 t(6;14)(q24;q24) UTRN::ENTPD5 t(6;16)(q23;q24) MYB::CHMP1A t(6;17)(q24;q11) AIG1::GOSR1 t(6;19)(p25;p13) NRN1::GNG7 t(6;21)(p22;q22) RUNX1::SUMO2P13 CLIC5::SUPT3H (6p21) KCNK17::KIF6 (6p21) LY6G5C::ABHD16A (6p21) SLC29A1::HSP90AB1 (6p21) SNHG5::SNX14 (6q14) t(6;6)(q14;q21) SENP6::NKAIN2 t(6;6)(q21;q23) EPB41L2::OSTM1 t(6;6)(q22;q23) L3MBTL3::PTPRK MYB::AHI1 (6q23) t(6;6)(q23;q24) MYB::PLAGL1 t(6;7)(p22;p14) MPLKIP::HIST1H1B t(6;7)(q14;p22) RAC1::COL12A1 t(6;7)(q21;p15) HOXA10-AS::CD164 t(6;7)(q23;q22) SLC12A9::MYB t(6;7)(q23;q36) MYB::MNX1 t(6;9)(p22;q34) NUP153::ABL1 t(6;9)(p24;p13) PAX5::TMEM14B del(6)(p21p21) ITPR3::PNPLA1 t(7;10)(q11;q24) CRCP::PIK3AP1 t(7;10)(q34;q24) TLX1::TRB t(7;11)(p15;p15) NUP98::HOXA11 t(7;11)(p15;q24) UBASH3B::TRA2A t(7;11)(p22;q23) KMT2A::TNRC18 t(7;11)(q21;q23) CDK6::KMT2A t(7;11)(q21;q23) KMT2A::RUNDC3B t(7;11)(q34;p15) RIC3::TRBC2 t(7;11)(q34;p15) RIC3::TRB t(7;12)(p12;p13) IKZF1::ETV6 t(7;12)(p12;q13) IKZF1::CDK2 t(7;12)(p14;p13) ETV6::ANLN t(7;12)(p14;p13) ETV6::ELMO1 t(7;12)(p22;q24) WIPI2::ERP29 t(7;13)(p21;q14) RB1::AGMO t(7;13)(q34;q14) ZC3HAV1::AKAP11 t(7;14)(p11;q32) IGH::EGFR t(7;14)(p14;q32) TRG::TCL1A t(7;14)(p14;q32) TRG::IGH t(7;14)(q21;q13) CDK6::NKX2-1 t(7;14)(q21;q32) IGH::ERVW-1 t(7;14)(q31;q32) IGH::IMMP2L t(7;15)(p12;q14) IKZF1::NUTM1 t(7;15)(p14;q21) GPR141::ONECUT1 t(7;15)(p14;q26) SLCO3A1::ELMO1 t(7;16)(q34;p13) CREBBP::TRBV23-1 t(7;17)(p12;p11) IKZF1::TRPV2 t(7;17)(q11;q25) FOXK2::CLIP2 t(7;19)(p15;p13) HOXA10::POLR2E t(7;19)(q21;p13) DNM2::HEPACAM2 t(7;19)(q31;q13) CAPZA2::TRIM28 t(7;20)(q34;q11) KIF3B::TRB t(7;20)(q36;p13) ESYT2::ATRN t(7;21)(p15;q22) RUNX1::EVX1 t(7;21)(q11;q22) RUNX1::UPK3B/DTX2 t(7;22)(p15;q13) EP300::HOXA7 t(7;22)(q34;q12) TRB::IL2RB t(7;7)(p11;p12) SEPT7P2::PSPH IKZF1::ABCA13 (7p12) t(7;7)(p12;p22) GRB10::SDK1 MIR550A1::ZNRF2 (7p14) t(7;7)(p14;p15) DPY19L1::HOXA11 t(7;7)(p15;p21) HOXA11::BZW2 t(7;7)(p15;q21) CDK6::RPL35P4 t(7;7)(p15;q21) HOXA11-AS::CDK6 inv(7)(p15q34)ort(7;7)(p15;q34) TRB::HOXA11 t(7;7)(p15;q34) TRB::HOXA9 NDUFA4::SCIN (7p21) t(7;7)(p21;q11) BZW2::GUSB GET4::TNRC18 (7p22) TTYH3::MAD1L1 (7p22) FAM133B::CDK6 (7q21) ZNF789::ZNF394 (7q22) t(7;7)(q22;q36) CUX1::ZNF398 CUL1::DPP6 (7q36) KMT2C::ACTR3B (7q36) t(7;8)(p15;q23) HOXA9::ANGPT1 t(7;8)(p15;q24) C8orf76::HOXA11-AS t(7;8)(p22;q11) PCMTD1::PRKAR1B t(7;8)(q22;p11) FGFR1::CUX1 t(7;8)(q22;p11) CUX1::FGFR1 t(7;8)(q34;q12) PLAG1::TRBJ2-7 t(7;9)(p22;q34) NUP214::RAC1 t(7;9)(q21;p13) PAX5::GRM3 inv(7)(p14q34) TRB::TRG inv(7)(p14q34) TRG::TRB inv(7)(q31q31) LAMB1::CAPZA2 t(8;10)(p23;q23) HELLS::CSMD1 t(8;11)(p12;p15) NUP98::NSD3 t(8;11)(q23;q22) TRPC6::NUDCD1 t(8;12)(q22;p13) ETV6::STK3 t(8;13)(q24;q13) PVT1::NBEA t(8;14)(q24;q11) TRD::PVT1 t(8;17)(q12;p11) NCOR1::LYN t(8;17)(q24;q25) RNF213::MYC t(8;19)(p11;q13) ERVK3-1::FGFR1 t(8;19)(p11;q13) KAT6A::LEUTX t(8;19)(q12;p13) GATAD2A::LYN t(8;19)(q24;q13) BCL3::MYC t(8;20)(q13;q11) NCOA6::PRDM14 t(8;21)(q21;q22) PDE9A::REXO1L1P HOOK3::FGFR1 (8p11) t(8;8)(p11;q24) POLB::LRRC6 t(8;8)(p21;p22) ENTPD4::PSD3 PVT1::ASAP1 (8q24) PVT1::NSMCE2 (8q24) t(8;9)(p21;p24) HMBOX1::JAK2 t(8;9)(p21;q21) TMEM2::PTK2B t(8;9)(q24;p13) MYC::ZBTB5 t(8;9)(q24;p13) MYC::ZCCHC7 t(8;9)(q24;p13) PVT1::ZCCHC7 t(8;9)(q24;q31) NRBP2::TMEM245 t(8;9)(q24;q31) UGCG::PVT1 t(9;10)(p11;p12) MLLT10::CNTNAP3B t(9;10)(p13;p14) PAX5::TAF3 t(9;10)(q34;q26) PRRC2B::MGMT t(9;11)(p13;p14) PAX5::KIAA1549L t(9;11)(p13;p15) DBX1::PAX5 t(9;11)(p13;q23) SHB::DDX6 t(9;11)(p24;q23) CBL::KANK1 t(9;11)(q22;q23) KMT2A::HABP4 t(9;11)(q34;q23) KMT2A::LAMC3 t(9;12)(p13;q24) FBRSL1::PAX5 t(9;12)(p13;q24) PAX5::FBRSL1 t(9;12)(p24;p13) ATF7IP::JAK2 t(9;12)(p24;p13) SMARCA2::ZNF384 t(9;12)(q34;q13) PCBP2::PRRC2B t(9;14)(p13;q24) PAX5::ESRRB t(9;14)(p21;q11) CDKN2A::TRA t(9;14)(p21;q11) TRA::CDKN2A t(9;14)(q21;q11) TRD::GNAQ t(9;14)(q34;q11) TRA::NOTCH1 t(9;15)(p13;q24) SIN3A::ANKRD18B t(9;15)(q34;q15) MAP1A::NUP188 t(9;16)(p13;q24) PAX5::CBFA2T3 t(9;16)(p13;q24) PAX5::ZNF276 t(9;16)(p24;p13) CIITA::CD274 t(9;16)(p24;p13) CIITA::PDCD1LG2 t(9;16)(p24;p13) JAK2::SNX29 t(9;16)(p24;p13) SNX29::JAK2 t(9;16)(q34;p11) FUS::SET t(9;16)(q34;p13) CIITA::RALGDS t(9;17)(p13;q21) PAX5::SP2 t(9;17)(p24;q21) SPAG9::JAK2 t(9;17)(q34;q25) ABL1::SLC9A3R1 t(9;17)(q34;q25) EGFL7::METRNL t(9;18)(p13;p11) EMILIN2::PAX5 t(9;19)(p13;p13) GRHPR::C3 t(9;19)(p13;p13) TMPRSS9::PAX5 t(9;19)(p24;p12) ZNF430::JAK2 t(9;19)(p24;q13) ZNF274::JAK2 t(9;19)(q22;q13) ERCC6L2::TGFB1 t(9;19)(q34;q13) LSM14A::ABL1 t(9;20)(p13;q13) PAX5::NCOA5 t(9;20)(p13;q13) SERINC3::ZCCHC7 t(9;20)(p13;q13) ZCCHC7::SERINC3 t(9;21)(p24;q21) USP25::JAK2 t(9;22)(q34;q11) BCR::RALGPS1/ABL1 t(9;22)(q34;q11) NUP214::XKR3 t(9;22)(q34;q11) PRRC2B::BCR HINT2::NPR2 (9p13) PAX5::RNF38 (9p13) PAX5::ZCCHC7 (9p13) UBAP1::DCAF12 (9p13) ZCCHC7::PAX5 (9p13) t(9;9)(p13;p21) PAX5::MLLT3 t(9;9)(p13;p24) PAX5::KANK1 t(9;9)(p13;q32) PAX5::FKBP15 t(9;9)(p13;q33) DENND1A::ZCCHC7 CDKN2A::IFNWP19 (9p21) CDKN2A::MTAP (9p21) t(9;9)(p21;p24) SMU1::JAK2 RFX3::JAK2 (9p24) SMARCA2::VLDLR (9p24) t(9;9)(p24;q22) BICD2::JAK2 PALM2::AKAP2 (9q31) t(9;9)(q31;q33) ZNF483::GAPVD1 t(9;9)(q33;q34) NR6A1::OBP2B ABL1::PRRC2B (9q34) EDF1::NOTCH1 (9q34) SEC16A::NOTCH1 (9q34) NUP214::ABL1 (9q34) del(9)(q22):del(9)(q22q31) TEX10::XPA del(9)(q34q34) NOTCH1::EDF1 dic(9;20)(p13;q11) PAX5::ASXL1 dic(9;20)(p13;q11) PAX5::NOL4L dic(9;20)(p13;q11) PAX5::KIF3B dic(9;20)(p13;q11) ZCCHC7::FRG1BP dic(9;20)(p13;q11 ZCCHC7::LOC1499503 ins(3;7)(q26;q34q22) TRB::MECOM ins(4;11)(q21;q23q23) DSCAML1::KMT2A ins(4;11)(q21;q23q23) FXYD6::KMT2A ins(10;11)(p12;q23q23) MLLT10::CLP1 ins(11;4)(q23;q21q24) NFKB1::KMT2A ins(11;4)(q23;q21q31) ELF2::KMT2A ins(15;17)(q22;q21q21) PML::CDC6/RARA ins(15;17)(q22;q21q26) PML::ADAMTS17/RARA ins(21;20)(q22;q11q11) RUNX1::CBFA2T2 ins(X;11)(q26;q23q23) KMT2A::CT45A2

Phylum and Thesaurus of Hematological malignancies (full table) detailed description ICD-O3 code Myeloproliferative neoplasms   Chronic myelogenous leukaemia, BCR-ABL1 positive 9975/3 Chronic neutrophilic leukaemia 9963/3 Polycythaemia vera 9950/3 Primary myelofibrosis 9961/3 Essential thrombocythaemia 9962/3 Chronic eosinophilic leukaemia, NOS 9964/3 Cutaneous mastocytosis 9740/3 Systemic mastocytosis 9741/3 Mast cell leukaemia 9742/3 Mast cell sarcoma 9740/3 Extracutaneous mastocytoma 9740/1 Myeloproliferative neoplasm, unclassifiable 9975/3 Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1   Myeloid and lymphoid neoplasms with PDGFRA rearrangement 9965/3 Myeloid and lymphoid neoplasms with PDGFRB rearrangement 9966/3 Myeloid and lymphoid neoplasms with FGFR1 rearrangement 9967/3 Myelodysplastic/myeloproliferative neoplasms   Chronic myelomonocytic leukaemia 9945/3 Atypical chronic myeloid leukaemia, BCR-ABL1 negative 9876/3 Juvenile myelomonocytic leukaemia 9946/3 Myelodysplastic/myeloproliferative neoplasm, unclassifiable 9975/3 Refractory anemia with ring sideroblasts associated with marked thrombocytosis 9982/3 Myelodysplastic syndromes   Refractory anemia 9980/3 Refractory neutropenia 9991/3 Refractory thrombocytopemia 9992/3 Refractory anaemia with ring sideroblasts 9982/3 Refractory cytopenia with multilineage dysplasia 9985/3 Refractory anaemia with excess blasts 9983/3 Myelodysplastic syndrome with isolated del(5q) 9986/3 Myelodysplastic syndrome, unclassifiable 9989/3 Childhood myelodysplastic syndrome NS Refractory cytopenia of childhood 9985/3 Acute myeloid leukaemia (AML) and related precursor neoplasms   AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 9896/3 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 9871/3 Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA 9866/3 AML with t(9;11)(p22;q23); MLLT3-MLL 9897/3 AML with t(6;9)(p23;q34); DEK-NUP214v 9865/3 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2);RPN1-EVI1 9869/3 AML (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1 9911/3 AML with mutated NPM1 9861/3 AML with mutated CEBPA 9861/3 AML with myelodysplasia-related changes 9895/3 Therapy-related myeloid neoplasms 9920/3 Acute myeloid leukaemia, NOS 9861/3 AML with minimal differentiation 9872/3 AML without maturation 9873/3 AML with maturation 9874/3 Acute myelomonocytic leukaemia 9867/3 Acute monoblastic and monocytic leukaemia 9891/3 Acute erythroid leukaemia 9840/3 Acute megakaryoblastic leukaemia 9910/3 Acute basophilic leukaemia 9870/3 Acute panmyelosis with myelofibrosis 9931/3 Myeloid sarcoma 9872/3 Transient abnormal myelopoiesis 9898/1 Myeloid leukaemia associated with Down syndrome 9898/3 Blastic plasmacytoid dendritic cell neoplasm 9727/3 Acute leukaemias of ambiguous lineage   Acute undifferentiated leukaemia 9801/3 Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1 9806/3 Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged 9807/3 Mixed phenotype acute leukaemia, B/myeloid, NOS 152 9808/3 Mixed phenotype acute leukaemia, T/myeloid, NOS 153 9809/3 Mixed phenotype acute leukaemia, NOS - rare types NS Other ambiguous lineage leukaemias NS Natural killer (NK)-cell lymphoblastic leukaemia/lymphoma NS Precursor lymphoid neoplasms   B lymphoblastic leukaemia/lymphoma, NOS 9811/3 B lymphoblastic leukaemia/lymphoma with t(9:22)(q34;q11.2); BCR-ABL1 9812/3 B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged 9813/3 B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 9814/3 B lymphoblastic leukaemia/lymphoma with hyperdiploidy 9815/3 B lymphoblastic leukaemia/lymphoma with hypodiploidy (Hypodiploid ALL) 9816/3 B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9817/3 B lymphoblastic leukaemia/lymphoma with t(1;19) (q23;p13.3); E2A-PBX1(TCF3-PBX1) 9818/3 T lymphoblastic leukaemia/lymphoma 9837/3 Mature B-cell neoplasms   Chronic lymphocytic leukaemia /small lymphocytic lymphoma 9823/3 B-cell prolymphocytic leukaemia 9833/3 Splenic marginal zone lymphoma 9689/3 Hairy cell leukaemia 9940/3 Splenic B-cell lymphoma/leukaemia, unclassifiable 9591/3 Splenic diffuse red pulp small B-cell lymphoma 9591/3 Hairy cell leukaemia-variant 9591/3 Lymphoplasmacytic lymphoma 9671/3 Waldenstrom macroglobulinemia 9761/3 Heavy chain diseases 9762/3 Gamma heavy chain disease 9762/3 Mu heavy chain disease 9762/3 Alpha heavy chain disease 9762/3 Plasma cell neoplasms - Monoclonal gammopathy of undetermined significance (MGUS) 9765/1 Plasma cell myeloma / Multiple myeloma 9732/3 Solitary plasmacytoma of bone 9731/3 Extraosseous plasmacytoma 9734/3 Monoclonal immunoglobulin deposition diseases - Extranodal marginal zone lymphoma of mucosa- associated lymphoid tissue (MALT lymphoma) 9699/3 Nodal marginal zone lymphoma 9699/3 Paediatric nodal marginal zone lymphoma 9699/3 Follicular lymphoma 9690/3 Paediatric follicular lymphoma 9690/3 Primary cutaneous follicle centre lymphoma 9597/3 Mantle cell lymphoma 9673/3 Diffuse large B-cell lymphoma (DLBCL), NOS 9680/3 T cell/histiocyte-rich large B-cell lymphoma 9688/3 Primary DLBCL of the CNS 9680/3 Primary cutaneous DLBCL, leg type 9680/3 EBV positive DLBCL of the elderly 9680/3 DLBCL associated with chronic inflammation 9680/3 Lymphomatoid granulomatosis 9766/3 Primary mediastinal (thymic) large B-cell lymphoma 9679/3 Intravascular large B-cell lymphoma 9712/3 ALK positive large B-cell lymphoma 9737/3 Plasmablastic lymphoma 9735/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9738/3 Primary effusion lymphoma 9678/3 Burkitt lymphoma 9687/3 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma 9680/3 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma 9596/3 Mature T- and NK-cell neoplasms   T-cell prolymphocytic leukaemia 9834/3 T-cell large granular lymphocytic leukaemia 9831/3 Chronic lymphoproliferative disorder of NK cells 9831/3 Aggressive NK cell leukaemia 9948/3 Systemic EBV+ T-cell lymphoproliferative disease of childhood 9724/3 Hydroa vacciniforme-like lymphoma 9725/3 Adult T-cell leukaemia/lymphoma 9827/3 Extranodal NK/T-cell lymphoma, nasal type 9719/3 Enteropathy-associated T-cell lymphoma 9717/3 Hepatosplenic T-cell lymphoma 9716/3 Subcutaneous panniculitis-like T-cell lymphoma 9708/3 Mycosis fungoides 9700/3 Sèzary syndrome 9701/3 Lymphomatoid papulosis 9718/1 Primary cutaneous anaplasic large cell lymphoma 9718/3 Primary cutaneous peripheral T-cell lymphomas, rare subtypes Primary cutaneous gamma-delta T-cell lymphoma 9726/3 Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma 9709/3 Primary cutaneous CD4 positive small/medium T-cell lymphoma 9709/3 Peripheral T-cell lymphoma, NOS 9702/3 Angioimmunoblastic T-cell lymphoma 9705/3 Anaplastic large cell lymphoma, ALK positive 9714/3 Anaplastic large cell lymphoma, ALK negative 9702/3 Hodgkin lymphoma   Nodular lymphocyte predominant Hodgkin lymphoma 9659/3 Classical Hodgkin lymphoma 9650/3 Nodular sclerosis classical Hodgkin lymphoma 9663/3 Mixed cellularity classical Hodgkin lymphoma 9652/3 Lymphocyte-rich classical Hodgkin lymphoma 9651/3 Lymphocyte-depleted classical Hodgkin lymphoma 9653/3 Immunodeficiency-associated lymphoproliferative disorders   Lymphoproliferative diseases associated with primary immune disorders NS Lymphomas associated with HIV infection NS Plasmatic hyperplasia 9971/1 Infectious mononucleosis-like PTLD 9971/1 Polymorphic PTLD 9971/3 Monomorphic PTLD (B- and T/NK-cell types, classified according to the leukemia/lymphomato which they correspond) - Classical Hodgkin lymphoma type PTLD - Histiocytic and dendritic cell neoplasms   Histiocytic sarcoma 9755/3 Langerhans cell histiocytosis 9751/3 Langerhans cell sarcoma 9756/3 Interdigitating dendritic cell sarcoma 9757/3 Follicular dendritic cell sarcoma 9758/3 Intermediate dendritic cell tumour 9759/3 Disseminated juvenile xanthogranuloma NS

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Thu Jan 20 18:14:53 CET 2022